Sensei Biotherapeutics Inc (SNSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has a cash flow conversion efficiency ratio of -0.056x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($191.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Sensei Biotherapeutics Inc for the company's overall valuation and market capitalisation.
Sensei Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Sensei Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sensei Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their cash flow conversion efficiency. See Sensei Biotherapeutics Inc (SNSE) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arima Communications Corp
TW:8101
|
-0.072x |
|
Superdong Fast Ferry Kien Giang JSC
VN:SKG
|
N/A |
|
Predictive Oncology Inc
NASDAQ:POAI
|
0.021x |
|
SciDev Limited
F:INFA
|
0.025x |
|
Haily Group Bhd
KLSE:0237
|
0.070x |
|
Neometals Ltd
AU:NMT
|
-0.236x |
|
RENALYTIX PLC LS-0025
F:2O9
|
N/A |
|
SPARK VC S.A. ZY 10
F:8N2
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Sensei Biotherapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Sensei Biotherapeutics Inc from 2018 to 2025. View Sensei Biotherapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.59 Million | $-20.45 Million | -1.100x | -71.17% |
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more